AbbVie

Open: 154.05 Close: 154.51 Change: 0.46

What an AI found about AbbVie after reading the whole Internet.

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Cerevel, Abbvie, Inc, stock, news, acquire, and the most common words in the summary are: abbvie, stock, market, price, top, buy, option, . One of the sentences in the summary was: In the last five years, earnings per share has shrunk at approximately 5.3% per …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. has a solid track record of paying dividends. In the last five years, earnings per share has shrunk at approximately 5.3% per annum. The mean historical PE ratio of ABBVie over the last ten years is 26.

Today's News

AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. abbvie inc. (abbv) news flow - moomoo. (abbv) News Flow - Moomoo. AbbVie (NYSE: ABBV) agreed to acquire the neuroscience drugmaker Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after the company agreed to buy the company for about $8.7 billion. Cerevel shares jumped some 12% today after Abbvie said it will buy the drug company. AbbVie Inc. has a solid track record of paying dividends. In the last five years, earnings per share has shrunk at approximately 5.3% per annum. Overall, we always like to see the dividend being raised, but we dont think Abbvie will make a great income stock. Alpine Immune Sciences has announced the amendment of the 2020 option and license agreement with AbbVie for acazicolcept. The amendment includes stopping enrollment in the phase 2 study of acazolcept in systemic lupus erythematosus to allow for early assessment of data, with the final analysis expected by the end of 2024. AbbVie is shelling out $10.1 billion for ADC maker ImmunoGen and its ovarian cancer med, Elahere. The Chicago pharma has snapped up Mitokinin and its preclinical Parkinsons candidate. The Field Access Specialist acts as an alternative in-office resource that is available to address HCP questions about patient access. At AbbVie, we conduct ground-breaking science on a global scal... at Abbvie. The following 128 pages are in category Drugs developed by AbbVie The mean historical PE ratio of ABBVie over the last ten years is 26.08. ABBVs current P/E ratio is above the 3, 5 and 10-year historical averages. AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. CEO Gonzalez brushes off FTC concerns for Cerevel buy: This acquisition is not anti-competitive. AbbVie Inc. beat two rival bidders to acquire immunogen for $10b, sec filings show – endpoints news. Abbvie had US$61.2b of debt at September 2023, down from US$70.0b a year prior. Warren Buffett famously said that Volatility is not synonymous with risk.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, Cerevel, Abbvie, Inc, stock, news, acquire, and the most common words in the summary are: abbvie, stock, market, price, top, buy, option, . One of the sentences in the summary was: In the last five years, earnings per share has shrunk at approximately 5.3% per annum. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #price #top #buy #option.